Jury orders Lilly, Takeda to pay $9 billion

FILE - Photo from Tuesday, July 17, 2012 shows the Eli Lilly corporate headquarters in Indianapolis. (AP File Photo/Michael Conroy)
FILE - Photo from Tuesday, July 17, 2012 shows the Eli Lilly corporate headquarters in Indianapolis. (AP File Photo/Michael Conroy)

TOKYO (AP) — A U.S. jury ordered Takeda Pharmaceutical Co. and Eli Lilly to pay $9 billion in punitive damages over a diabetes medicine linked to cancer, but Japan’s biggest drugmaker said Tuesday it will “vigorously challenge” the decision.

The District Court, Western District Louisiana, ordered a $6 billion penalty for Takeda and $3 billion for its business partner and co-defendant Eli Lilly. It also decided $1.5 million in compensatory damages in favor of the plaintiff.

The legal fight turned on whether Actos, which is a drug used to treat type-two diabetes, caused a patient’s bladder cancer and by implication was responsible for other cases of the cancer. Takeda and Eli Lilly are facing numerous other lawsuits over the drug, which allege failure to warn about side effects and concealment of its health risks.

Kenneth Greisman, a general counsel at Takeda, said in a statement that the evidence does not support a link between Actos and bladder cancer.

“Takeda respectfully disagrees with the verdict, and we intend to vigorously challenge this outcome through all available legal means, including possible post-trial motions and an appeal,” he said.

Punitive damages are often reduced on appeal.

In June 2011, the U.S. Food and Drug Administration published a drug safety update on Actos, which said there was a 40 percent increase in bladder cancer risk in people who used the drug for longer than a year. It required that the cancer risk be added to the medication’s warning label. Actos has been sold since 1999.

Actos comes with warnings about serious side effects, including liver problems, broken bones and higher risk of bladder cancer.

Osaka-based Takeda shares tanked on the Tokyo Stock Exchange, closing down 5.2 percent.

blog comments powered by Disqus